PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations

(2015) Katsuhiko Nosho et al.   NEOPLASIA

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

(2012) Arjun Sood et al.   Clinical Colorectal Cancer

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

(2012) Paola Ulivi et al.   Journal of Translational Medicine

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

(2012) Ignacio Garrido-Laguna et al.   PLoS One

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

(2011) H. Hayashi et al.   ANNALS OF ONCOLOGY

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

(2011) C. Mao et al.   ANNALS OF ONCOLOGY

Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study

(2011) Giuseppe Colucci et al.   ONCOLOGY

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

(2011) Zacharenia Saridaki et al.   PLoS One

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

(2010) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

(2009) J Souglakos et al.   BRITISH JOURNAL OF CANCER

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

(2009) H. Prenen et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

(2009) Y. He et al.   CLINICAL CANCER RESEARCH

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined

(2008) E. D. Saad et al.   ANNALS OF ONCOLOGY

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY